Liver-Directed and Systemic Therapy Options for Hepatocellular Carcinoma

Presented by:
Rajiv Agarwal
Search for other papers by Rajiv Agarwal in
Current site
Google Scholar
PubMed Close
 MD
and
Lea K. Matsuoka
Search for other papers by Lea K. Matsuoka in
Current site
Google Scholar
PubMed Close
 MD
Moderated by:
Daniel B. Brown
Search for other papers by Daniel B. Brown in
Current site
Google Scholar
PubMed Close
 MD, FSIR
Volume/Issue:
Volume 20: Issue 5.5
Online Publication Date:
02 Jun 2022
DOI:
https://doi.org/10.6004/jnccn.2022.5017
Restricted access

Abstract

Liver transplant and resection are preferable for the management of hepatocellular carcinoma, but ultimately, tumor location, biology, and patient condition dictate treatment decisions. At the NCCN 2022 Annual Conference, a panel of experts used 3 case studies to develop an evidence-based approach to the treatment of similar patients with hepatocellular carcinoma. Moderated by Daniel B. Brown, MD, FSIR, the session focused on current research regarding liver-directed and systemic therapy options.

Disclosures: Drs. Agarwal and Matsuoka have disclosed having no relevant financial relationships. Dr. Brown has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP, Bard Medical, Ipsen, and Sirtex Medical; serving on the product/speaker’s bureau for Cook Medical; and receiving grant/research support from Guerbet and Sirtex.

Correspondence: Rajiv Agarwal, MD, Vanderbilt University Medical Center, 2220 Pierce Avenue, Preston Research Building 777, Nashville, TN 37232. Email: rajiv.agarwal@vumc.org; Lea K. Matsuoka, MD, Vanderbilt University Medical Center, 1313 21st Avenue South, 801 Oxford House, Nashville, TN 37232. Email: lea.matsuoka@vumc.org; and Daniel B. Brown, MD, FSIR, Vanderbilt University, 1161 21st Avenue South, CCC-1118 Medical Center North, Nashville, TN 37232. Email: daniel.b.brown@vumc.org
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Fan ST, Lo CM, Poon RTP, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011;253:745–758.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Llovet JM, Fuster J, Bruix J, et al. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434–1440.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Weis S, Franke A, Mössner J, et al. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev 2013;CD003046.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;57:794–802.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010;252:903–912.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Liu H, Wang ZG, Fu SY, et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 2016;103:348–356.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–700.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022;76:681–693.

  • 9.

    Benson AB, D’Angelica MI, Abbott DE, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Hepatobiliary Cancers. Version 1.2022. Accessed April 6, 2022. Available at NCCN.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 2021;74:2342–2352.

  • 11.

    Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015;61:1968–1977.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Mehta N, Frenette C, Tabrizian P, et al. Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium. Gastroenterology 2021;161:1502–1512.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Sinha J, Mehta N, Dodge JL, et al. Are there upper limits in tumor burden for down-staging of hepatocellular carcinoma to liver transplant? Analysis of the all-comers protocol. Hepatology 2019;70:1185–1196.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: a phase 3, multicenter, randomized controlled trial. J Clin Oncol 2022;40:380–380.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894–1905.

  • 16.

    Finn RS, Qin S, Ikeda M, et al. IMbrave150: updated overall survival data from a global, randomized, open-label phase III study of atezolizumab + bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma [abstract ]. J Clin Oncol 2021;39(Suppl):Abstract 267.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA [abstract ]. J Clin Oncol 2022;40(Suppl):Abstract 379.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017;18:1624–1636.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71–81.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2022 by the National Comprehensive Cancer Network 2022
Page Numbers:
5
Article Category:
Research Article
Print Publication Date:
01 May 2022
Online Publication Date:
02 Jun 2022

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1120 178 5
PDF Downloads 462 105 8
EPUB Downloads 0 0 0